In breast cancer, METTL16 can stabilize the expression of GPX4 by increasing its m6A methylation, and GPX4 further reduces the levels of intracellular iron, Fe2+ and lipid reactive oxygen species (ROS), inhibits the occurrence of ferroptosis173. Here, GPX4 is linked to breast cancer.